Visual acuity

Visual acuity (VA) is acuteness or clearness of vision, which is dependent on the sharpness of the retinal focus within the eye and the sensitivity of the interpretative faculty of the brain. Visu...

Polo like kinase Plk 1

Polo-like kinase (Plk) is an important cell cycle regulatory kinase that has been implicated in a multitude of cell cycle events. Plks form a family of four different proteins that regulates many as...

Herpes simplex virus HSV 1 HSV 2 HHV 1 HHV 2

Herpes simplex virus 1 and 2 (HSV-1 and HSV-2), also known as Human herpes virus 1 and 2 (HHV-1 and -2), are two members of the herpes virus family that infect humans. HSV-1 and HSV-2 cause the vira...

The Top 100 Drugs

The pharmaceutical industry is massive, both in range of products and in financial values. These are the top 200 drugs (ranked in descending order according to total sales in 20010, $), and the co...

Astellas, AstraZeneca announce Symbicort Turbuhaler approval in Japan

Astellas Pharma and AstraZeneca have announced the approval of the dry-power inhaler Symbicort Turbuhaler for the additional indication of chronic obstructive pulmonary disease (COPD).

Astellas and AstraZeneca announce the approval in Japan of the dry-power inhaler Symbicort® Turbuhaler® for the additional indication of chronic obstructive pulmonary disease (COPD)

Tokyo, Japan, August 10, 2012 – Astellas Pharma Inc. (“Astellas”, headquarters: Tokyo; President and CEO: Yoshihiko Hatanaka) and AstraZeneca K.K. (“AstraZeneca”, headqua...

Japan widens OK of AstraZeneca and Astellas' Symbicort Turbuhaler

Japanese regulators approved AstraZeneca and Astellas Pharma's Symbicort Turbuhaler to treat chronic obstructive pulmonary di -More- 

Astellas gets expanded approval for Symbicort asthma drug in Japan

TOKYO, June 22 (Reuters) - Astellas Pharma Inc said on Friday it has received approval for additional use of its Symbicort Turbuhaler drug treatment for adult bronchial asthma in Japan beyond its curr...

Single Use Symbicort Approved For Adult Bronchial Asthma

Astellas Pharma and AstraZeneca announced approval of a new administration method/dosage in addition to the current maintenance therapy of Symbicort　Turbohaler (generic: budesonide/formoterol fumari...

Symbicort budesonide/formoterol: Postmarketing study data

Symbicort® Maintenance And Reliever Therapy for Treatment of Adult Bronchial Asthma Approved in Japan (pdf 73 KB)

GSK’s Breo Ellipta Approved With COPD Airflow Obstruction, Exacerbation Claims

Once-daily dosing provides a convenience advantage over the other inhaled corticosteroid/long-acting beta-agonist combination products on the COPD market: GlaxoSmithKline’s own Advair and AstraZenec...

Budesonide/Formoterol turbuhaler®: a review of its use in chronic obstructive pulmonary disease.

Chronic obstructive pulmonary disease (COPD) is a highly heterogeneous, progressive inflammatory disease that imposes considerable economic and healthcare burdens on society, with the disease predicte...

Dose emission and aerodynamic characterization of the terbutaline sulphate dose emitted from a Turbuhaler at low inhalation flow.

Previously, dose emission below 30 L min(-1) through DPI has not been routinely determined. However, during routine use some patients do not achieve 30 L min(-1) inhalation flows. Hence, the aim o...

Unaffected peak inspiratory flow through Turbuhaler during histamine inhalation challenge.

Errors in turbuhaler technique in a spanish population of asthmatic patients.

Budesonide/formoterol maintenance and reliever therapy in primary care asthma management: effects on bronchial hyperresponsiveness and asthma control.

BACKGROUND: The management of asthma has changed since the introduction of budesonide/formoterol (Symbicort®) as both maintenance and reliever therapy (SMART). SMART and its effects on bronchial hyp...